Clinical translation requires human CSF pharmacokinetic assays to prove BBB bypass, a rigorous dose-escalation Phase I trial to establish a safe human NOAEL for chronic dosing, and an RCT utilizing precise neurocognitive testing (e.g., MoCA) to confirm that murine transcriptomic shifts yield functional neuroprotection in humans
The legitimate path is opening back up, and it is worth doing this right
"Endometriosis: Etiology, pathobiology, and therapeutic prospects"
Most patients report early changes (improved skin feel, reduced inflammation, or fewer shedding hairs) by the end of week 3 or 4
Chronic fatigue syndrome combines increased exercise-induced oxidative stress and reduced cytokine and Hsp responses
Notably, G/D-CuP exerted anti-inflammatory and antioxidative properties, promoting angiogenesis, fibroblast proliferation, and migration to accelerate wound healing without the need for additional bioactive substances